Jennison Associates LLC Increases Stake in Edwards Lifesciences Corporation $EW

Jennison Associates LLC increased its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 19.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 13,958,774 shares of the medical research company’s stock after buying an additional 2,287,783 shares during the period. Jennison Associates LLC owned about 2.38% of Edwards Lifesciences worth $1,085,574,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in EW. Vanguard Group Inc. increased its position in shares of Edwards Lifesciences by 1.2% in the 2nd quarter. Vanguard Group Inc. now owns 69,997,629 shares of the medical research company’s stock valued at $5,474,515,000 after purchasing an additional 798,801 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Edwards Lifesciences by 0.4% during the 2nd quarter. Geode Capital Management LLC now owns 12,722,416 shares of the medical research company’s stock worth $990,074,000 after purchasing an additional 45,555 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its stake in shares of Edwards Lifesciences by 111.2% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock worth $714,006,000 after purchasing an additional 4,805,819 shares in the last quarter. Ninety One UK Ltd increased its holdings in Edwards Lifesciences by 14.0% in the third quarter. Ninety One UK Ltd now owns 7,908,572 shares of the medical research company’s stock valued at $615,050,000 after buying an additional 969,030 shares during the last quarter. Finally, Norges Bank acquired a new stake in Edwards Lifesciences in the second quarter valued at $580,640,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 11,340 shares of the company’s stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $85.66, for a total transaction of $971,384.40. Following the completion of the sale, the vice president owned 31,870 shares in the company, valued at $2,729,984.20. This represents a 26.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Scott B. Ullem sold 7,700 shares of the stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total value of $650,419.00. Following the sale, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at approximately $3,370,184.06. This represents a 16.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 57,824 shares of company stock valued at $4,863,323 in the last ninety days. Insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

EW has been the subject of several analyst reports. The Goldman Sachs Group reaffirmed a “buy” rating and set a $108.00 price objective on shares of Edwards Lifesciences in a research report on Friday, January 9th. Barclays reaffirmed an “overweight” rating and issued a $104.00 price target (up from $103.00) on shares of Edwards Lifesciences in a report on Monday, January 12th. Citigroup reissued a “buy” rating and set a $101.00 price objective (up previously from $96.00) on shares of Edwards Lifesciences in a report on Thursday, December 11th. Truist Financial set a $92.00 price objective on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, December 5th. Finally, Canaccord Genuity Group set a $87.00 target price on shares of Edwards Lifesciences and gave the company a “hold” rating in a research report on Wednesday, December 17th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average price target of $96.82.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $83.70 on Friday. The stock has a market capitalization of $48.57 billion, a price-to-earnings ratio of 36.08, a PEG ratio of 3.22 and a beta of 0.95. The firm’s fifty day simple moving average is $84.99 and its 200-day simple moving average is $80.80. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.89.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The company had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period in the previous year, the business posted $0.67 earnings per share. Edwards Lifesciences’s quarterly revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.